← Back to Search

Cancer Vaccine

AV-GBM-1 for Glioblastoma

Phase 2
Waitlist Available
Research Sponsored by Aivita Biomedical, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial will test a new vaccine for brain cancer. The vaccine will be made from the patient's own cells, and will be tested on approximately 55 patients.

Eligible Conditions
  • Glioblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Efficacy Endpoint: Overall Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: AV-GBM-1Experimental Treatment1 Intervention
Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.

Find a Location

Who is running the clinical trial?

Aivita Biomedical, Inc.Lead Sponsor
7 Previous Clinical Trials
990 Total Patients Enrolled
1 Trials studying Glioblastoma
672 Patients Enrolled for Glioblastoma
Robert O Dillman, MDStudy ChairAivita Biomedical, Inc.
7 Previous Clinical Trials
878 Total Patients Enrolled
1 Trials studying Glioblastoma
672 Patients Enrolled for Glioblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can AV-GBM-1 be legally prescribed in the United States?

"Given that this is a Phase 2 trial - meaning there has been some evidence to support safety, but not efficacy - our team at Power have given AV-GBM-1 a score of 2."

Answered by AI

I am interested in enrolling myself in this research project, what are the next steps?

"The study needs 55 individuals that have glioblastoma and are between 18-70 years old. Most importantly, patients should the following prerequisites: They must be starting concurrent CT/RT soon and have a Karnofsky Performance Score of 70-100%."

Answered by AI

At how many distinct hospitals is this clinical trial being carried out?

"There are a total of 8 participating clinical sites, with locations in Orange, Louisville and Newport Beach. To minimize the inconvenience of travel for potential participants, it is best to choose the clinic located nearest you."

Answered by AI

Are patients being accepted into the trial at this time?

"As can be seen on clinicaltrials.gov, this trial is not currently recruiting patients for participation. Although the study is no longer active, it originally was posted on June 20th, 2018 and edited December 14th, 2021. There are 458 other trials searching for patients right now."

Answered by AI

Would it be possible to enroll elderly patients in this experiment?

"Patients that wish to enroll in this study must be between 18-70 years old. There are 35 similar trials for minors and 431 for elderly patients."

Answered by AI

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
2018. "Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03400917.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top